Offer - Urjas Oil for just ₹ 1 X
Tapal 150 Tablet (10) is a prescription drug, available for use as Tablet. It is primarily used for the treatment of Pain. Tapal 150 Tablet (10) also has some secondary and off-label uses. These are listed below.
The correct dosage of Tapal 150 Tablet (10) depends on the patient's age, gender, and medical history. The condition it has been prescribed for, and the route of administration also determine the right dosage. Refer to the dosage section for a detailed discussion.
While these are the most often observed Tapal 150 Tablet (10) side effects, there are can be others also. These have been listed below. Normally, these side effects of Tapal 150 Tablet (10) are not long lasting and go away when the treatment is finished. Consult your doctor if these side effects become worse or stay for a longer duration.
Tapal 150 Tablet (10)'s effect during pregnancy is Moderate and Severe while nursing. Warnings related to Tapal 150 Tablet (10)'s effects on the liver, heart and kidney, if any, have been listed below.
Tapal 150 Tablet (10) can cause adverse effects in certain medical conditions. It is strongly recommended to avoid Tapal 150 Tablet (10) in conditions like Asthma, Liver Disease, Kidney Disease. Some other conditions that can be affected by Tapal 150 Tablet (10) are listed in the contraindications section below.
Besides this, Tapal 150 Tablet (10) may also have severe interaction with some medicines. A complete list of these interactions is given below.
In addition to the above precautions for Tapal 150 Tablet (10), it is important to know that it is not safe while driving, and is not habit-forming.
Tapal 150 Tablet (10) is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
Is the use of Tapal 150 Tablet (10) safe for pregnant women?
Tapal can have harmful effects in pregnant women. If you experience any discomfort after using Tapal, then discontinue the use and take your doctor's advice.
Is the use of Tapal 150 Tablet (10) safe during breastfeeding?
Tapal may cause serious side effects in breastfeeding women, so do not take this drug without doctor's advice.
What is the effect of Tapal 150 Tablet (10) on the Kidneys?
Very few cases of side effects of Tapal on kidney have been reported.
What is the effect of Tapal 150 Tablet (10) on the Liver?
Tapal has very mild side effects on the liver.
What is the effect of Tapal 150 Tablet (10) on the Heart?
Side effects of Tapal rarely affect the heart.
If you are suffering from any of the following diseases, you should not take Tapal 150 Tablet (10) unless your doctor advises you to do so -
Is this Tapal 150 Tablet (10) habit forming or addictive?
Yes, you can get addicted to Tapal 150 Tablet (10). It is essential that you take [medicine] only after doctor's recommendation.
Is it safe to drive or operate heavy machinery when consuming?
After taking Tapal 150 Tablet (10) you may feel sleepy. So it is not advised to perform these activities.
Is it safe?
Yes, Tapal 150 Tablet (10) is safe but you must consult your doctor before taking it.
Is it able to treat mental disorders?
There is no benefit of taking Tapal 150 Tablet (10) for mental disorders.
Interaction between Food and Tapal 150 Tablet (10)
It is safe to take Tapal 150 Tablet (10) with food.
Interaction between Alcohol and Tapal 150 Tablet (10)
Consuming Tapal 150 Tablet (10) with alcohol can have many serious effects on your body.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Nucynta® (tapentadol)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1173-1175